Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESI + -MS Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
      Carcinoma, Papillary*/metabolism ; Thyroid Nodule*/diagnosis ; Selenium* ; Thyroid Neoplasms*/pathology; Humans ; Chromatography, High Pressure Liquid ; Thyroid Cancer, Papillary/diagnosis ; Thyroid Cancer, Papillary/metabolism ; Metabolome ; Biomarkers/metabolism ; Lipids ; Biomarkers, Tumor/metabolism
    • نبذة مختصرة :
      In this study, serum metabolic profiling of patients diagnosed with papillary thyroid carcinoma (PTC) and benign thyroid pathologies (BT) aimed to identify specific biomarkers and altered pathways when compared with healthy controls (C). The blood was collected after a histological confirmation from PTC (n = 24) and BT patients (n = 31) in parallel with healthy controls (n = 81). The untargeted metabolomics protocol was applied by UHPLC-QTOF-ESI + -MS analysis and the statistical analysis was performed using the MetaboAnalyst 5.0 platform. The partial least squares-discrimination analysis, including VIP values, random forest graphs, and heatmaps ( p < 0.05), was complemented with biomarker analysis (with AUROC ranking) and pathway analysis, suggesting a model for abnormal metabolic pathways in PTC and BT based on 166 identified metabolites. There were 11 classes of putative biomarkers selected that were involved in altered metabolic pathways, e.g., polar molecules (amino acids and glycolysis metabolites, purines and pyrimidines, and selenium complexes) and lipids including free fatty acids, bile acids, acylated carnitines, corticosteroids, prostaglandins, and phospholipids. Specific biomarkers of discrimination were identified in each class of metabolites and upregulated or downregulated comparative to controls, PTC group, and BT group. The lipidomic window was revealed to be more relevant for finding biomarkers related to thyroid carcinoma or benign thyroid nodules, since our study reflected a stronger involvement of lipids and selenium-related molecules in metabolic discrimination.
    • References:
      J Occup Environ Med. 2020 Jan;62(1):1-3. (PMID: 31626062)
      Nat Rev Mol Cell Biol. 2019 Jun;20(6):353-367. (PMID: 30814649)
      Cancer. 2017 Feb 1;123(3):372-381. (PMID: 27741354)
      Diagnostics (Basel). 2022 Jan 27;12(2):. (PMID: 35204408)
      Front Oncol. 2022 Dec 22;12:1076548. (PMID: 36620583)
      Expert Rev Anticancer Ther. 2008 Sep;8(9):1399-413. (PMID: 18759692)
      Front Cell Dev Biol. 2021 Jun 21;9:682269. (PMID: 34235148)
      Front Immunol. 2021 Aug 30;12:728381. (PMID: 34539667)
      Molecules. 2022 Feb 18;27(4):. (PMID: 35209182)
      Int J Cancer. 2021 Sep 1;149(5):984-992. (PMID: 34013533)
      J Proteome Res. 2015 Aug 7;14(8):3315-21. (PMID: 26130307)
      Clin Diabetes Endocrinol. 2016 Oct 3;2:17. (PMID: 28702251)
      Int J Environ Res Public Health. 2019 Apr 02;16(7):. (PMID: 30986998)
      Endokrynol Pol. 2017;68(4):440-465. (PMID: 28819948)
      Int J Endocrinol. 2017;2017:1297658. (PMID: 28255299)
      Biomark Med. 2020 Jun;14(9):807-815. (PMID: 32677454)
      Mol Biosyst. 2011 Sep;7(9):2608-14. (PMID: 21713270)
      Biomed Res Int. 2017;2017:2545031. (PMID: 29234677)
      Int J Endocrinol. 2015;2015:258763. (PMID: 25972898)
      Clin Endocrinol (Oxf). 2017 Aug;87(2):117-126. (PMID: 28493290)
      ACS Omega. 2023 Mar 07;8(11):10355-10364. (PMID: 36969406)
      J Occup Environ Med. 2016 Mar;58(3):299-305. (PMID: 26949881)
      Endocrine. 2013 Dec;44(3):616-22. (PMID: 23645523)
      Cancer Manag Res. 2019 Feb 25;11:1829-1841. (PMID: 30881111)
      J Clin Endocrinol Metab. 2022 Dec 17;108(1):13-25. (PMID: 36181451)
      Endocr Relat Cancer. 2019 Dec 1;26(12):829-841. (PMID: 31671400)
      Front Cell Dev Biol. 2021 Feb 01;9:593510. (PMID: 33598460)
      Trends Biochem Sci. 2014 Mar;39(3):112-20. (PMID: 24485058)
      Crit Rev Clin Lab Sci. 2017 Nov - Dec;54(7-8):446-457. (PMID: 29084467)
      Front Cell Dev Biol. 2020 Jun 16;8:385. (PMID: 32612989)
      Molecules. 2021 Nov 23;26(23):. (PMID: 34885664)
      Metabolites. 2022 Nov 21;12(11):. (PMID: 36422294)
      Ann Oncol. 2019 Dec 1;30(12):1856-1883. (PMID: 31549998)
      Tumour Biol. 2016 Aug;37(8):11163-75. (PMID: 26935059)
      PLoS One. 2012;7(11):e48873. (PMID: 23139822)
      Thyroid. 2013 Sep;23(9):1079-86. (PMID: 23350941)
      Int J Mol Sci. 2020 Jul 24;21(15):. (PMID: 32722293)
      Biomarkers. 2017 Nov;22(7):595-603. (PMID: 27805426)
      Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi. (PMID: 17673125)
      Scand J Surg. 2004;93(4):278-81. (PMID: 15658668)
      Anal Bioanal Chem. 2014 Jul;406(18):4357-70. (PMID: 24842401)
      CA Cancer J Clin. 2021 Jul;71(4):333-358. (PMID: 33982817)
      Occup Environ Med. 2014 May;71(5):366-80. (PMID: 24604144)
      Biol Trace Elem Res. 2015 Oct;167(2):225-35. (PMID: 25820485)
    • Grant Information:
      881/39/12.01.2022 Iuliu Hațieganu University of Medicine and Pharmacy
    • Contributed Indexing:
      Keywords: benign nodules; biomarker and pathway analysis; oncometabolites; papillary thyroid cancer; serum metabolomics
    • الرقم المعرف:
      H6241UJ22B (Selenium)
      0 (Biomarkers)
      0 (Lipids)
      0 (Biomarkers, Tumor)
    • الموضوع:
      Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC10970441
    • الرقم المعرف:
      10.3390/ijms25063495
    • الرقم المعرف:
      38542465